Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DE:4DN)
:4DN
4DN Analyst Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
4DN Stock 12 Month Forecast
Average Price Target
€37.51
▲(84.40% Upside)
| Highest Price Target€83.14 | Average Price Target€37.51 | Lowest Price Target€22.93 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Deutsche Bank
Initiated
02/11/25
Stifel Nicolaus
Reiterated
02/10/25
Goldman Sachs
Reiterated
01/28/25
BTIG
Reiterated
01/21/25
TD Cowen
Reiterated
01/14/25
Morgan Stanley
Reiterated
01/13/25
Bank of America Securities
Reiterated
01/13/25
J.P. Morgan
Reiterated
01/07/25
H.C. Wainwright
Reiterated
01/07/25
Jefferies
Assigned
01/07/25
B.Riley Financial
€36.24
Buy
78.15%
Upside
Reiterated
01/07/25
Denali Therapeutics: Strategic Pipeline Potential and Investment Opportunity Amid Recent Setbacks
Robert W. Baird
€29.56
Buy
45.33%
Upside
Initiated
01/06/25
Baird starts Denali Therapeutics Inc. (DNLI) at OutperformBaird analyst Joel Beatty initiates coverage on Denali Therapeutics Inc. (NASDAQ: DNLI) with a Outperform rating and a price target of $31.00.
William Blair
€33.37
Buy
64.08%
Upside
Initiated
01/03/25
Denali Therapeutics initiated with an Outperform at William BlairDenali Therapeutics initiated with an Outperform at William Blair
Oppenheimer
€47.68
Buy
134.40%
Upside
Reiterated
11/11/24
Oppenheimer Sticks to Their Buy Rating for Denali Therapeutics (DNLI)
Leerink Partners
€38.14
Buy
87.52%
Upside
Reiterated
11/07/24
Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
Best Analysts Covering Denali Therapeutics
Which Analyst Should I Follow If I Want to Buy DE:4DN and Sell After:
1 Month
xxx
Success Rate
10/13 ratings generated profit
Average Return
+8.12%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 76.92% of your transactions generating a profit, with an average return of +8.12% per trade.
3 Months
xxx
Success Rate
9/14 ratings generated profit
Average Return
+18.69%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +18.69% per trade.
1 Year
Success Rate
10/12 ratings generated profit
Average Return
+15.43%
reiterated a buy rating 2 months ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +15.43% per trade.
2 Years
xxx
Success Rate
9/12 ratings generated profit
Average Return
+7.98%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +7.98% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
4DN Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Strong Buy
10
7
5
15
13
Buy
10
12
8
10
5
Hold
3
4
3
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
23
16
26
18
Each month's total comprises the sum of three months' worth of ratings.
4DN Financial Forecast
4DN Stock Forecast FAQ
What is DE:4DN’s average 12-month price target, according to analysts?
Based on analyst ratings, Denali Therapeutics’s 12-month average price target is €37.51.
What is DE:4DN’s upside potential, based on the analysts’ average price target?
Denali Therapeutics has 84.40% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Denali Therapeutics a Buy, Sell or Hold?
Denali Therapeutics has a consensus rating of Strong Buy, which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
What is Denali Therapeutics’s share price target?
The average share price target for Denali Therapeutics is €37.51. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €83.14 ,and the lowest forecast is €22.93. The average share price target represents 84.40% Increase from the current price of €20.34.
The highest analyst share price target is €83.14 ,and the lowest forecast is €22.93. The average share price target represents 84.40% Increase from the current price of €20.34.
What do analysts say about Denali Therapeutics?
Denali Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of Denali Therapeutics?
To buy shares of DE:4DN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.